Add to ORKGphase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic non-small cell lung cance
Purpose:This phase III study compared the efficacy and tolerability of gemcitabine and oxaliplatin (...
A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfami...
Introduction: This study compared survival without toxicity in patients with advanced, nonsquamous n...
Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung can...
Background: Paclitaxel administered in combination with a topoisomerase-II inhibitor (such as etopos...
Back Ground: Non small cell lung cancer (NSCLC) constitutes about 75-80 % of all lung cancer cases. ...
The backbone of treatment in advanced non-small cell lung cancer is platinum-based doublet chemother...
Objective: It is important to identify optimal regimens of cisplatin-based, third-generation che-mot...
Approximately one-third of all cancer-related deaths in Western countries are due to lung cancer. No...
Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclita...
A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cispl...
Free to read at publisher's site. INTRODUCTION: Performance status (PS) 2 patients with non-small ce...
Free to read at publisher's site.\ud \ud INTRODUCTION: \ud Performance status (PS) 2 patients with n...
INTRODUCTION: This study compared survival without toxicity in patients with advanced, nonsquamous n...
NOTE: THE SYMBOLS/SPECIAL CHARACTERS IN THIS ABSTRACT CANNOT BE DISPLAYED CORRECTLY ON THIS PAGE. PL...
Purpose:This phase III study compared the efficacy and tolerability of gemcitabine and oxaliplatin (...
A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfami...
Introduction: This study compared survival without toxicity in patients with advanced, nonsquamous n...
Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung can...
Background: Paclitaxel administered in combination with a topoisomerase-II inhibitor (such as etopos...
Back Ground: Non small cell lung cancer (NSCLC) constitutes about 75-80 % of all lung cancer cases. ...
The backbone of treatment in advanced non-small cell lung cancer is platinum-based doublet chemother...
Objective: It is important to identify optimal regimens of cisplatin-based, third-generation che-mot...
Approximately one-third of all cancer-related deaths in Western countries are due to lung cancer. No...
Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclita...
A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cispl...
Free to read at publisher's site. INTRODUCTION: Performance status (PS) 2 patients with non-small ce...
Free to read at publisher's site.\ud \ud INTRODUCTION: \ud Performance status (PS) 2 patients with n...
INTRODUCTION: This study compared survival without toxicity in patients with advanced, nonsquamous n...
NOTE: THE SYMBOLS/SPECIAL CHARACTERS IN THIS ABSTRACT CANNOT BE DISPLAYED CORRECTLY ON THIS PAGE. PL...
Purpose:This phase III study compared the efficacy and tolerability of gemcitabine and oxaliplatin (...
A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfami...
Introduction: This study compared survival without toxicity in patients with advanced, nonsquamous n...